Hemophilia ANCT07523399
Joint Health, Balance and Quality of Life in Adults With Hemophilia A
An observational study of Hemophilia A, run by Yuzuncu Yil University at 1 site in Turkey (Türkiye).
Trial summary
Hemophilia is a hereditary bleeding disorder characterized by recurrent bleeding episodes, particularly into joints and muscles, leading to chronic musculoskeletal complications. Read more about this study
- Who is it for?
- Ages 18 to 65 years, men only
- Conditions the study is for
- Hemophilia A
- How many people
- 36 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 21 Feb 2026to 21 May 2026
- How long will I take part?
- 2 Weeks
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: Adults with hemophilia A
Who may be able to join
- Diagnosis of severe hemophilia A
- Age ≥18 years
- A minimum single-joint score of 3 points for the knee or ankle according to the Hemophilia Joint Health Score (HJHS)
Who cannot join
- Use of walking aids (e.g., crutches)
- Presence of neurological or psychiatric disorders, chronic inflammatory disease, -Regular use of medications that could affect balance,
- History of major lower extremity surgery within the previous six months.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Van Yuzuncu Yil University
Van, 65080
Ayse Merve Tat, Assistant Professor, +905052431112, aysemervetat@yyu.edu.tr
About this study
Official title: Quality of Life in Adults With Hemophilia A: Associations With Joint Health, Pain, Dynamic Balance, and Falls
Hemophilia is a hereditary bleeding disorder characterized by recurrent bleeding episodes, particularly into joints and muscles, leading to chronic musculoskeletal complications. Repeated joint bleeding may result in hemophilic arthropathy, which is associated with progressive joint damage, chronic pain, reduced mobility, and functional limitations. Advances in prophylactic treatment have significantly improved life expectancy in individuals with hemophilia; however, long-term musculoskeletal complications continue to affect daily functioning and overall well-being. Therefore, the evaluation of health-related quality of life (QoL) has become increasingly important in adults with hemophilia, as it reflects the broader impact of the disease beyond clinical severity.
Joint health is considered one of the major determinants of physical functioning in people with hemophilia. Hemophilic arthropathy may lead to chronic pain, muscle weakness, reduced range of motion, and impaired physical performance. In addition to structural joint changes, impairments in neuromuscular function, including reduced proprioception, muscle strength, and postural control, may also contribute to activity limitations. Balance impairments may increase the risk of falls, which may be particularly relevant for individuals with hemophilia because fall-related trauma can lead to bleeding episodes and further joint deterioration. Although previous studies have investigated the relationship between joint health, pain, and functional limitations, the combined contribution of joint health, pain severity, dynamic balance performance, and fall history to QoL in adults with hemophilia has not been sufficiently clarified.
Read more
This prospective cross-sectional study aims to evaluate QoL in adults with hemophilia and to investigate the associations of joint health, pain severity, dynamic balance performance, and fall history with QoL outcomes. The study includes 36 adults diagnosed with severe hemophilia A who are followed at the Adult Hematology Unit of Van Yuzuncu Yil University. Participants aged 18 years and older who met the inclusion criteria were recruited consecutively. Individuals using walking aids, having neurological or psychiatric disorders, chronic inflammatory diseases, recent lower extremity surgery, or regular medication use that could affect balance were excluded.
Joint health is assessed using the Hemophilia Joint Health Score (HJHS), a clinician-administered tool evaluating joint impairment in the knees and ankles. Dynamic balance is assessed using a computerized stabilometric platform (Pro-kin Tecnobody Stabilometric Analysis System) with the Limits of Stability (LoS) test, which evaluates the ability to voluntarily control the center of pressure within the base of support. Pain intensity is measured using the Numeric Pain Rating Scale (NPRS), an 11-point scale ranging from 0 to 10. Fall history is determined based on the self-reported number of falls within the previous 12 months. QoL is assessed using the Turkish version of the Haemophilia-Specific Quality of Life Questionnaire for adults (Haem-A-QoL), a validated patient-reported outcome measure evaluating multiple domains of physical, emotional, and social well-being. Higher scores indicate poorer QoL.
The findings of this study are expected to improve the understanding of factors associated with QoL in adults with hemophilia and may help identify potentially modifiable clinical targets for rehabilitation interventions.
- Conditions
- Hemophilia A
- Keywords
- Quality of life, Hemophilia A, Arthropathy, Postural balance, Falls, Musculoskeletal Pain
- Medical subject headings
- Hemophilia A, Joint Diseases, Musculoskeletal Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Hemophilia A | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Health-related quality of life
Health-related quality of life will be assessed using the Haemophilia-Specific Quality of Life Questionnaire for Adults (Haem-A-QoL). The total score ranges from 0 to 100, with higher scores indicating poorer quality of life.
Measured: Baseline
Joint Health
Joint health will be evaluated using the Hemophilia Joint Health Score (HJHS). Higher scores indicate poorer joint health status.
Measured: Baseline
Postural Balance
Dynamic postural balance were evaluated with the Pro-kin Technobody Posturographic Platform (Pro-kin 212, Technobody s.r.l, Dalmine, 21044 Bergamo, Italy).
Measured: Baseline
Secondary outcomes (2)
Musculoskeletal Pain
Pain severity will be measured using the Numeric Pain Rating Scale (NPRS), ranging from 0 (no pain) to 10 (worst possible pain).
Measured: Baseline
Falls
Fall history will be assessed as the self-reported number of falls experienced within the previous 12 months.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2026
- Study start21 Feb 2026
- Primary completion21 Apr 2026 (estimated)
- Study completion21 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Hemophilia AStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 36 participants (estimated)
- Target duration
- 2 Weeks
Sponsor and investigators
- Lead sponsor
- Yuzuncu Yil University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ayse Merve TAT, Yuzuncu Yil University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07523399
- Sponsor's protocol ID
- YuzuncuYil2026-QoL
- Status last verified
- Apr 2026
- First submitted
- 4 Apr 2026
- Last updated
- 13 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Tat NM, Tat AM, Dogan A. Association of musculoskeletal impairments and balance with quality of life in adults with severe hemophilia A: a cross-sectional study. BMC Musculoskelet Disord. 2026 Jul 31;27(1):763. doi: 10.1186/s12891-026-10309-x.
PubMed 42717340